Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999723 | 0.88 | HTR6 (0.62) | HTR6KMT2ANPSR1METPOLB | |
| SCHEMBL15514563 | 0.78 | LDHA (0.64) | FABP4FABP5RXFP1KMT2AMAPK10 | |
| SCHEMBL10693393 | 0.77 | LDHA (0.63) | HTR6POLBGAAGFERLDHA | |
| SCHEMBL6548757 | 0.77 | ALDH1A1 (0.54) | HTR6FABP4KMT2ANPSR1MET | |
| SCHEMBL3578778 | 0.76 | FABP4 (0.51) | FABP4FABP5RXFP1KMT2AMAPK10 | |
| SCHEMBL2385214 | 0.76 | RXFP1 (0.46) | HTR6FABP4FABP5RXFP1KMT2A | |
| SCHEMBL15461558 | 0.76 | RXFP1 (0.50) | FABP4FABP5RXFP1KMT2AMAPK10 | |
| SCHEMBL30987398 | 0.76 | RXFP1 (0.46) | HTR6FABP4FABP5RXFP1KMT2A | |
| SCHEMBL3833910 | 0.75 | CA1 (0.58) | HTR6KMT2ANPSR1POLBGAA | |
| SCHEMBL6614757 | 0.74 | FABP4 (0.50) | FABP4FABP5RXFP1KMT2AMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | HTR6, TPH1, HTR5A | HTR6 1/4885FABP4 1927/4885FABP5 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.